11/9/2010

Japanese regulators have granted marketing approval for Revolade, a blood-disorder drug by Ligand Pharmaceuticals and GlaxoSmithKline. The treatment is approved in Europe under the same brand and is sold in the U.S. as Promacta.

Related Summaries